Publications by authors named "Gregory Golm"

Claim this Profile
P
Prior Effective Sample Size When Borrowing on the Treatment Effect Scale.
Hongtao Zhang, Keaven M Anderson, Zachary Zimmer, Gregory Golm, Aditi Sapre

Stat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of composite time-to-event endpoints in cardiovascular outcome trials.
Rachel Marceau West, Gregory Golm, Devan V Mehrotra

Clin Trials· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust analyzes for longitudinal clinical trials with missing and non-normal continuous outcomes.
Siyi Liu, Yilong Zhang, Gregory T Golm, Guanghan Frank Liu, Shu Yang

Stat Theory Relat Fields· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
R Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Gregory T Golm

Pediatr Diabetes· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Muhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S Newfield, Gregory T Golm

Pediatr Diabetes· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data with Informative Censoring.
Guoqing Diao, Guanghan F Liu, Donglin Zeng, Yilong Zhang, Gregory Golm

Stat Biopharm Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Priscilla Hollander, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm

Curr Med Res Opin· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How 4 Companies Became One: Co-development Under an Outsourced Model With Focus on Phase 3 Analysis and Reporting Deliverables.
Susan Huyck, Gregory Golm, Sajda Ghani, James Mancuso, Tarra Irvin

Ther Innov Regul Sci· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Ronan Roussel, Santiago Duran-García, Yilong Zhang, Suneri Shah, Carolyn Darmiento, Gregory T Golm

Diabetes Obes Metab· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Christopher P Cannon, Darren K McGuire, Richard Pratley, Sam Dagogo-Jack, James Mancuso, Gregory Golm

Am Heart J· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Priscilla A Hollander, Wendy L Carofano, Raymond L H Lam, Gregory T Golm, Roy Eldor

Diabetes Obes Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Philip D Home, Raymond L H Lam, Wendy L Carofano, Gregory T Golm, Roy Eldor

Diabetes Obes Metab· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Richard E Pratley, Roy Eldor, Annaswamy Raji, Gregory Golm, Susan B Huyck

Diabetes Obes Metab· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Samuel Dagogo-Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Gregory Golm

Diabetes Obes Metab· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
George Grunberger, Sarah Camp, Jeremy Johnson, Susan Huyck, Steven G Terra, Gregory Golm

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.
Sam Miller, Tania Krumins, Haojin Zhou, Susan Huyck, Jeremy Johnson, Gregory Golm

Diabetes Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Control-based imputation for sensitivity analyses in informative censoring for recurrent event data.
Fei Gao, Guanghan F Liu, Donglin Zeng, Lei Xu, Bridget Lin, Gregory Golm

Pharm Stat· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Gregory Golm

Diabetes Obes Metab· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
Robert G Moses, Elizabeth Round, Yue Shentu, Gregory T Golm, Edward A O'neill

J Diabetes· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co-administered to Chinese patients with type 2 diabetes mellitus.
Linong Ji, Ping Han, Xiaoyue Wang, Jingdong Liu, Shaoxiong Zheng, Gregory T Golm

J Diabetes Investig· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine.
Chantal Mathieu, R Ravi Shankar, Daniel Lorber, Guillermo Umpierrez, Fan Wu, Gregory T Golm

Diabetes Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Paul Hartley, Yue Shentu, Patricia Betz-Schiff, Gregory T Golm, Christine McCrary Sisk

Drugs Aging· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.
Elizabeth M Round, Samuel S Engel, Gregory T Golm, Michael J Davies, Keith D Kaufman

Drugs Aging· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on: Butler et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
Samuel S Engel, Gregory T Golm, Brett Lauring

Diabetes· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis